Cooperative Agreement U01CA296659
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $625K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- Federal Cooperative Agreement Summary The Salk Institute for Biological Studies received a $745,320 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025, through August 31, 2030. The award funds a five-year research initiative investigating the role of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) in regulating inflammatory signals associated with pancreatic ductal adenocarcinoma...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement valued at $639,882 to the University of North Carolina at Chapel Hill (UNC-CH), Office of Sponsored Research, effective August 1, 2025, through July 31, 2030, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research into the molecular mechanisms underlying metastasis organ tropism—specifically, why certain breast cancer subtypes preferentially...
- Federal Cooperative Agreement Summary The University of Southern California received a $531,693 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on August 4, 2025, with a completion date of July 31, 2030. This award supports research to develop a validated computational model of the tumor-immune ecosystem in breast cancer. The project will deliver an agent-based computational model that captures tumor-immune...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $922,755 to the University of Massachusetts Medical School on August 28, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate tRNA modification reprogramming and translational remodeling in cancer. The five-year project, scheduled for completion on July 31, 2030, will comprehensively examine how chemical modifications of transfer RNA (tRNA) and their...
- Cooperative Agreement Summary The National Cancer Institute awarded a $556,865 Cooperative Agreement to Trustees of Tufts College under the Cancer Biology Research program (CFDA 93.396) on September 1, 2025, with a completion date of August 31, 2030. This five-year research initiative investigates stiffness-mediated genetic selection of cells, examining how mechanical properties of substrates select for cellular variants adapted to growth on soft or stiff environments. The research extends...
- Federal Project Grant Award Summary The University of Colorado-Denver received a $547,080 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 17, 2025 through August 31, 2029. This award supports the University of Colorado Cancer Center's (UCCC) initiative to advance cancer screening and prevention clinical trials. Under the direction of Dr. Wood, the Deputy Director of the Cancer Control Program, the funded...
- Federal Cooperative Agreement Summary The University of Pittsburgh received a $360,643 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through August 31, 2030. This award supports preanalytical validation research for circulating tumor DNA (ctDNA) and tumor-derived exosomes (TEX) as biomarkers of postoperative minimal residual disease (MRD) in head and neck squamous cell carcinoma (HNSCC)....
- Federal Cooperative Agreement Award Summary The National Cancer Institute awarded $323,226 to the University of Michigan's Office of Research and Sponsored Projects under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2028. This Cooperative Agreement funds research focused on developing natural products targeting interleukin-8 (IL-8) signaling to intercept the progression of Barrett's esophagus to esophageal adenocarcinoma (EAC), a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $584,510 to the University of Colorado-Denver on September 12, 2025, under the Cancer Biology Research program (CFDA 93.396) to support the development and implementation of advanced spatial transcriptomics and proteomics technologies for studying tumor microenvironments. Through the Human Immune Monitoring Shared Resource (HIMSR) at the University of Colorado Cancer Center, this funding supports a...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded $941,798 to Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) on August 6, 2025, for a five-year initiative concluding July 31, 2030. This cooperative agreement supports fundamental research investigating the mechanism and therapeutic implications of RNA-modification-mediated codon-biased translation in acute myeloid leukemia (AML). The research focuses on...